Ceterizine

DRUG3 trials

Sponsors

Genzyme, a Sanofi Company, Maryam Lustberg

Conditions

Metastatic HR+/HER2- Breast CancerMultiple SclerosisProgressive Multiple Sclerosis

Phase 1

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

CompletedNCT02583594

Genzyme, a Sanofi CompanyProgressive Multiple Sclerosis

Start: 2015-12-06End: 2021-03-01Updated: 2021-03-10

Phase 2

Rash & Diarrhea Prophylaxis With Capivasertib

Not yet recruitingNCT07426822

Maryam LustbergMetastatic HR+/HER2- Breast Cancer

Start: 2026-04-01End: 2029-04-01Target: 108Updated: 2026-02-24

Phase 3

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

TerminatedNCT03368664

Genzyme, a Sanofi CompanyMultiple Sclerosis

Start: 2017-10-24End: 2025-09-08Updated: 2025-11-26

Related Papers

SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis.

2024-11-06